Early diagnosis of relapsing prostate cancer is one of the most important factors determining patient survival. Positron emission tomography/computed tomography (PET/CT) is successfully utilized in this setting. Studies show that prostate‑specific membrane antigen (PSMA) radiotracers, especially those labelled with fluorine 18 (18F), seem to have the highest specificity and sensitivity among other prostate cancer tracers. In this systematic review the authors present a current state of the art of PET/CT imaging using 18F‑PSMA‑1007, a radiopharmaceutical which in the papers published to date showed the best pharmacokinetic and pharmacodynamic properties, and the highest diagnostic sensitivity in relapsing prostate cancer patients.